4,045 Danaher Corporation $DHR Shares Purchased by RDA Financial Network

RDA Financial Network raised its stake in Danaher Corporation (NYSE:DHR) by 166.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,468 shares of the conglomerate’s stock after buying an additional 4,045 shares during the period. RDA Financial Network’s holdings in Danaher were worth $1,433,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Marquette Asset Management LLC raised its position in shares of Danaher by 192.1% during the third quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC acquired a new position in shares of Danaher in the second quarter worth approximately $25,000. Main Street Group LTD acquired a new position in shares of Danaher in the first quarter worth approximately $25,000. Field & Main Bank bought a new stake in Danaher in the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. boosted its holdings in Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Wall Street Analyst Weigh In

A number of research firms have weighed in on DHR. The Goldman Sachs Group increased their target price on shares of Danaher from $210.00 to $250.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Morgan Stanley upped their price objective on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research note on Monday. Wells Fargo & Company decreased their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. Finally, Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $235.41.

Danaher Stock Up 3.0%

Shares of Danaher stock opened at $231.52 on Friday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock’s 50-day moving average is $213.55 and its 200 day moving average is $195.74. The firm has a market cap of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 earnings per share. Equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.